{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:57:43Z","timestamp":1792735063671,"version":"4.5.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00415-023-11846-4","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T08:01:35Z","timestamp":1689148895000},"page":"5188-5195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group\u200f Viewpoint"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-6292","authenticated-orcid":false,"given":"Panayiota","family":"Petrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Achiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Ganelin","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Garty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Magalashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Karmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Milo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Wilf-Yarkoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Karussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"11846_CR1","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","volume":"23","author":"SG Meuth","year":"2022","unstructured":"Meuth SG, Bayas A, Kallmann B, Linker R, Rieckmann P, Wattjes MP, M\u00e4urer M, Kleinschnitz C (2022) Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother 23:1503\u20131510. https:\/\/doi.org\/10.1080\/14656566.2022.2106783","journal-title":"Expert Opin Pharmacother"},{"key":"11846_CR2","doi-asserted-by":"publisher","first-page":"577966","DOI":"10.1016\/j.jneuroim.2022.577966","volume":"372","author":"D Magalashvili","year":"2022","unstructured":"Magalashvili D, Mandel M, Dreyer-Alster S, Didikin M, Harari G, Flechter S, Achiron A (2022) Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4. J Neuroimmunol 372:577966. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577966","journal-title":"J Neuroimmunol"},{"key":"11846_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","volume":"11","author":"V Meca-Lallana","year":"2022","unstructured":"Meca-Lallana V, Garc\u00eda Dom\u00ednguez JM, L\u00f3pez Ruiz R, Mart\u00edn-Mart\u00ednez J, Ar\u00e9s Luque A, Hern\u00e1ndez P\u00e9rez MA, Prieto Gonz\u00e1lez JM, Landete Pascual L, Sastre-Garriga J (2022) Expert-agreed practical recommendations on the use of cladribine. Neurol Ther 11:1475\u20131488. https:\/\/doi.org\/10.1007\/s40120-022-00394-0","journal-title":"Neurol Ther"},{"key":"11846_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S\u00f8rensen P, Vermersch P, Chang P, Hamlett A, Musch B et al (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa0902533","journal-title":"N Engl J Med"},{"key":"11846_CR5","doi-asserted-by":"publisher","first-page":"104459","DOI":"10.1016\/j.msard.2022.104459","volume":"69","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, Kleinschnitz C, Havrdova EK, Magyari M, Selchen D et al (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler Relat Disord 69:104459. https:\/\/doi.org\/10.1016\/j.msard.2022.104459","journal-title":"Mult Scler Relat Disord"},{"key":"11846_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P (2018) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler 24:1594\u20131604. https:\/\/doi.org\/10.1177\/1352458517727603","journal-title":"Mult Scler"},{"key":"11846_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","volume":"12","author":"M Habek","year":"2023","unstructured":"Habek M, Drulovic J, Brecl Jakob G, Barbov I, Radulovic L, Rajda C, Rejdak K, Tur\u010d\u00e1ni P (2023) Treatment with cladribine tablets beyond year 4: a position statement by southeast european multiple sclerosis centers. Neurol Ther 12:25\u201337. https:\/\/doi.org\/10.1007\/s40120-022-00422-z","journal-title":"Neurol Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11846-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11846-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11846-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:03:11Z","timestamp":1697274191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11846-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["11846"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11846-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"13 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"None of the authors of this manuscript, participants of this committee, has any conflict of interest, for any possible contribution of the conclusions presented in this article, in the development of future protocols for the long term use of Cladribine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}